In the third quarter, Banyan Capital Management Inc. initiated a position in Johnson & Johnson, acquiring 3,853 shares valued at approximately $714,000. This stake represents roughly 0.3% of Banyan’s portfolio and ranks as its 22nd largest holding. Other notable moves include Norges Bank establishing a new Johnson & Johnson stake worth $4.88 billion in Q2, Laurel Wealth Advisors increasing its share count by 7.37 million (a 15,040.6% rise) to a holding valued at $1.13 billion, and Vanguard Group boosting its position by 3.09 million shares to 237.05 million shares worth over $36.2 billion. Institutional ownership now stands at 69.55%.

The Committee for Medicinal Products for Human Use issued a favorable opinion on AKEEGA (niraparib plus abiraterone) for BRCA1/2-mutant metastatic hormone-sensitive prostate cancer, potentially adding a new oncology revenue stream. Following the company’s Q4 results, Daiwa Capital Markets raised its price target to $237 and maintained an Outperform rating. Morgan Stanley upgraded the stock citing a stronger growth outlook, and Scotiabank lifted its target to $265 while reiterating Outperform. Wall Street commentary remains broadly positive but measured, with consensus targets clustered near $233.05.

Investors received relief when a U.S. district judge dismissed a fraud lawsuit challenging the company’s talc bankruptcy strategy, removing a near-term liability overhang. However, some legal analysts caution that broader talc litigation remains unresolved. Separately, reports surfaced that the CEO sold approximately $22 million of personal shares following Q4 results, prompting questions around insider governance despite company explanations.

In Q4, Johnson & Johnson delivered EPS of $2.46, matching consensus, and reported revenue of $24.56 billion, up 9.1% year-over-year. Net margin reached 28.46% and return on equity was 33.34%. The firm has set full-year 2026 EPS guidance between $11.43 and $11.63. On the shareholder returns front, the board declared a quarterly dividend of $1.30 per share, translating to a 2.3% yield and continuing a 63-year streak of annual increases.